# Best Peptides for Mitochondrial Dysfunction & Cellular Energy: What the Evidence Actually Shows

> A clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.

*Published 2026-07-01 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The honest headline
Of the entire peptide universe, **only elamipretide (SS-31) has direct human evidence that it improves cellular energy production** — a single infusion raised muscle ATP output about 27% in older adults, but the effect faded within a week and never improved fatigue. The other three candidates — **MOTS-c, humanin and the SHLP family** — are biologically fascinating but their efficacy evidence is almost entirely preclinical (Grade C). No peptide is proven to durably fix mitochondria or boost energy in humans.[1](https://peptidevox.com/#r1)[29](https://peptidevox.com/#r29)

Mitochondrial dysfunction is a real, well-recognized driver of fatigue, exercise intolerance and age-related decline — and it is also a magnet for peptide marketing that runs far ahead of the human data. The peptides discussed here are either unapproved investigational compounds or, in one case, approved only for an ultra-rare disease. This article is informational and editorial content only — *not* medical advice, *not* a protocol to follow, and *not* a sourcing or buying guide. Dosing is reported strictly "as seen in the literature and FDA labeling" for completeness. Most peptides here are investigational or unapproved for human use; do not self-administer, and consult a licensed clinician before any health decision.

## Do any peptides actually fix mitochondrial dysfunction?

The short answer is no proven one — with a single, narrow exception. Mitochondria generate roughly 90% of cellular ATP through oxidative phosphorylation, and their decline (through cardiolipin oxidation, cristae collapse, electron-transport-chain inefficiency, reactive-oxygen-species accumulation and reduced biogenesis) is a recognized cause of fatigue, muscle weakness and age-related disability.[1](https://peptidevox.com/#r1)[11](https://peptidevox.com/#r11) Peptides have been proposed to intervene at three mechanistically distinct nodes, but only one has ever produced a human energy signal.

The one peptide with direct human evidence is **elamipretide (SS-31)**. In a randomized, double-blind, placebo-controlled trial in 39 healthy older adults selected for poor muscle mitochondrial function, a single two-hour infusion raised the maximal rate of ATP production (ATPmax) by roughly 27% immediately post-dose — the first demonstration that a drug can acutely reverse mitochondrial dysfunction in living human muscle.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) But the effect faded within a week and did not translate into measured fatigue resistance, and the full peer-reviewed trial is available on [PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/PMC8282018/). The critical caveat that governs this entire category is that mechanistic elegance has repeatedly failed to translate into human outcomes: across four large randomized trials, elamipretide missed every primary clinical endpoint.[3](https://peptidevox.com/#r3) The mitochondrial-derived peptides (MOTS-c, humanin, SHLP) have even less human data.

## Which peptides are the strongest candidates, ranked by evidence?

Ranking reflects the strength of evidence relevant to human cellular energy, not mechanistic elegance or popularity. Because only elamipretide has any human bioenergetic data, the ranking is essentially how close each peptide's evidence comes to a demonstrated human energy effect.

  Peptide candidates for mitochondrial dysfunction — evidence at a glance (2026)

    PeptideMitochondrial node targetedBest human dataEnergy grade

    Elamipretide (SS-31)Cardiolipin / cristae & electron-transport-chain stabilizationRCT raised muscle ATPmax ~27% (acute, reversible; no fatigue benefit); FDA-approved for Barth onlyB
    MOTS-cAMPK activation & mitochondrial biogenesisRodent + biomarker only; first human RCT recruiting Feb 2026; WADA-bannedC
    Humanin (HNG)Anti-apoptotic retrograde signaling (BAX/tBID, gp130/STAT3)Observational only; no interventional human trial; tumor-promotion caveatC
    SHLP family / MDP axisComplex-I support, biogenesis (PGC-1α, mtDNA), ROS reductionSerum association only; no human efficacy trial; SHLP6 is pro-apoptoticC
    Exercise (context; NOT a peptide)Endogenous MDP induction + biogenesisRaises muscle MOTS-c ~12-fold and humanin; robust human evidenceA

**Elamipretide (SS-31)** ranks first by a wide margin because it is the only candidate with a human RCT showing a cellular-energy effect.[1](https://peptidevox.com/#r1) Unlike most drugs it acts on no cell-surface receptor: it crosses into mitochondria, concentrates several-thousand-fold, and binds cardiolipin — the phospholipid that scaffolds cristae and clusters the oxidative-phosphorylation complexes into supercomplexes — stabilizing structure and reducing electron leak.[3](https://peptidevox.com/#r3) Its preclinical case is strong: in aged mice SS-31 reversed the age-related decline in ATPmax and P/O coupling and improved exercise tolerance.[11](https://peptidevox.com/#r11)[13](https://peptidevox.com/#r13) But its clinical record is mixed-to-negative — MMPOWER-3 in mitochondrial myopathy, PROGRESS-HF in heart failure, EMBRACE-STEMI in acute MI and ReCLAIM-2 in dry AMD all missed their primary endpoints — and its single FDA approval (Forzinity, September 2025) is for Barth syndrome only.[7](https://peptidevox.com/#r7)[6](https://peptidevox.com/#r6)

**MOTS-c** is the most clinically advanced mitochondrial-derived peptide. Encoded within mitochondrial DNA, it activates AMPK — the master cellular energy sensor — positioning it as an exercise-mimetic signal.[14](https://peptidevox.com/#r14) Its preclinical energy data are the strongest in the category: late-life treatment roughly doubled treadmill running capacity in old mice.[15](https://peptidevox.com/#r15) But there is no completed human efficacy trial; circulating MOTS-c merely tracks with age and metabolic health, and the first dedicated Phase 2a RCT — registered as [NCT07505745](https://clinicaltrials.gov/study/NCT07505745) — only began recruiting in February 2026 and targets insulin sensitivity, not ATP output.[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17) MOTS-c is also banned by WADA at all times as an AMPK activator.[19](https://peptidevox.com/#r19)

**Humanin** and the **SHLP family** are the founding and broader members of the mitochondrial-derived-peptide axis. Humanin is a legitimate endogenous cytoprotective signal that blocks BAX/tBID-mediated apoptosis and signals through a gp130/STAT3–AKT–ERK survival axis, but it has never been tested in any interventional human trial; its human footprint is purely observational (higher in children of centenarians; lower levels track with faster cognitive aging).[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)[22](https://peptidevox.com/#r22) SHLP2, the most bioenergetic member, binds respiratory complex I, raises oxygen-consumption rate and ATP, and increases mtDNA copy number and PGC-1α — but only in cell and animal models.[28](https://peptidevox.com/#r28)[27](https://peptidevox.com/#r27) Crucially, the SHLPs are heterogeneous: SHLP2 and SHLP3 are cytoprotective, but SHLP6 is pro-apoptotic, so 'SHLP' is not one benign drug.[26](https://peptidevox.com/#r26)

## What does the evidence NOT support?

Claims that outrun the data
"Peptides can fix mitochondrial dysfunction," "SS-31 durably boosts energy or athletic performance," "MOTS-c is exercise in a vial," and "humanin/SHLP are proven longevity therapies" are all ahead of the evidence. Elamipretide — the most validated — missed the primary endpoints of four large RCTs, and the MDPs have no completed human efficacy trial at all.[3](https://peptidevox.com/#r3)

Take each in turn. "SS-31 durably boosts energy" fails because the one human bioenergetic study showed an acute ATPmax rise that vanished within seven days and did not improve fatigue.[1](https://peptidevox.com/#r1) "MOTS-c is exercise in a vial" fails because the doubled-running-capacity finding is in aged mice, there is no completed human efficacy trial, and in humans exercise *raises* MOTS-c — the causality runs the way the marketing reverses it.[15](https://peptidevox.com/#r15)[17](https://peptidevox.com/#r17) "Humanin and SHLP are proven longevity therapies" fails because both are supported only by preclinical and observational data; humanin's pivotal mouse study failed to extend lifespan and it carries a tumor-promotion signal, and no SHLP has any human efficacy trial.[20](https://peptidevox.com/#r20)[24](https://peptidevox.com/#r24)[26](https://peptidevox.com/#r26) And "more MDP signaling is always better" fails because a hemodialysis cohort found a U-shaped humanin–mortality association, and SHLP6 is pro-apoptotic.[23](https://peptidevox.com/#r23)[26](https://peptidevox.com/#r26)

For perspective on what strong human evidence actually looks like, the single intervention with robust data for raising mitochondrial-peptide signaling is not a peptide at all: **exercise** induces roughly a 12-fold rise in skeletal-muscle MOTS-c and raises humanin, durably and safely.[15](https://peptidevox.com/#r15) From a functional-medicine, root-cause standpoint, the most defensible interventions for mitochondrial energy remain the upstream ones — training, sleep, correcting nutrient and hormonal deficiencies, reducing toxic load, and treating genuine mitochondrial disease through specialist care — not an unregulated injectable.[16](https://peptidevox.com/#r16)

## What are the safety, legal and anti-doping realities in 2026?

Safety differs sharply by candidate. Elamipretide is consistently benign in its trial program — predominantly injection-site reactions and transient eosinophilia — though its benzyl-alcohol excipient makes it unsuitable for neonates and renal impairment requires dose reduction.[4](https://peptidevox.com/#r4) The unapproved MDPs are a different story: **humanin carries an animal-demonstrated tumor-promotion and chemoresistance signal**, protecting triple-negative breast-cancer and glioblastoma cells from apoptosis, and some SHLPs (notably SHLP6) are pro-apoptotic — so they are not interchangeably 'benign.'[24](https://peptidevox.com/#r24)[25](https://peptidevox.com/#r25)[26](https://peptidevox.com/#r26) The dominant practical hazard of all unregulated peptides is immunogenicity and impurity from uncharacterized manufacture.[30](https://peptidevox.com/#r30)

On US regulation: only elamipretide is FDA-approved, and only for Barth syndrome — all other uses are investigational.[5](https://peptidevox.com/#r5) MOTS-c sat in FDA compounding Category 2 from 2023, was removed around April 2026, and faces a Pharmacy Compounding Advisory Committee review on July 23–24, 2026, but removal from Category 2 does not authorize compounding.[30](https://peptidevox.com/#r30)[31](https://peptidevox.com/#r31) Humanin and SHLPs are sold solely as 'research use only / not for human consumption' reagents with no legal human-administration pathway.[34](https://peptidevox.com/#r34)[35](https://peptidevox.com/#r35) On anti-doping, MOTS-c is prohibited at all times under WADA S4.4.1 (AMPK activators) with no therapeutic-use exemption; elamipretide, humanin and SHLPs are not individually named but, as substances not approved for general human use, plausibly fall under WADA S0, and athletes bear strict liability.[32](https://peptidevox.com/#r32)[33](https://peptidevox.com/#r33)

**Bottom line.** The mechanistic biology of these peptides is real and compelling, but the human outcome data are thin to absent. Elamipretide is the strongest by a wide margin and the only one with a human energy signal — yet that signal was acute, reversible, surrogate-level, and produced no functional benefit, and the drug is approved for one ultra-rare disease. MOTS-c, humanin and the SHLPs are Grade C, preclinical throughout. Anyone presenting a peptide as a proven fix for mitochondrial dysfunction or 'low energy' is far ahead of the evidence. Regulatory and trial facts here are current as of June 2026 and should be re-verified as the FDA compounding review and new trials report.

---
Source: https://peptidevox.com/energy-cognition-mood/peptides-for-mitochondrial-dysfunction
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt